Bystander Effects in Enzyme/Prodrug Gene Therapy

This publication has 10 references indexed in Scilit:

• Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 Gene
  Human Gene Therapy, 1997
• The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable Metabolite
  Human Gene Therapy, 1997
• The TMC Worldwide Gene Therapy Enrollment Report, End 1996. Report of TMC Development, Paris, France
  Human Gene Therapy, 1997
• Immune system in suicide-gene therapy
  The Lancet, 1997
• Gene Therapy for Metastatic Malignant Melanoma: Evaluation of Tolerance to Intratumoral Injection of Cells Producing Recombinant Retroviruses Carrying the Herpes Simplex Virus Type 1 Thymidine Kinase Gene, to be Followed by Ganciclovir Administration. Laboratoire Immunologie B, Hôpital Pitié-Salpêtrière, Paris Cedex, France
  Human Gene Therapy, 1996
• Activation of the Radiosensitive EGR-1 Promoter Induces Expression of the Herpes Simplex Virus Thymidine Kinase Gene and Sensitivity of Human Glioma Cells to Ganciclovir
  Human Gene Therapy, 1995
• Metabolic suicide genes in gene therapy
  Pharmacology & Therapeutics, 1994
• Cancer gene therapy: A bystander effect using the gap junctional pathway
  Molecular Carcinogenesis, 1994
• Ex Vivo Gene Therapy of Familial Hypercholesterolemia. Howard Hughes Medical Institute, University of Michigan
  Human Gene Therapy, 1992
• Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population.
  Proceedings of the National Academy of Sciences, 1992